Aging
Navigate
Submit an Article
Research Paper|Volume 11, Issue 17|pp. 7187–7196
STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway
Back to articleFigure 6(6 of 6)
100%
Figure 6
Figure 6.Proposed model. Pictures showing that AZ628 and BP-1-102 combination inhibits RAS-mutant lung cancer cells by markedly abrogating MEK/ERK signaling pathway activation.